Additional efficacy endpoints from the phase 3 KEYNOTE‑355 study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer - Rugo, H S; Schmid, P; Cescon, D W (San Antonio Breast Cancer Symposium 2020, 2020)
. Online (Stand: 16.03.2021):